Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Collins

Showing results (121-130 of 247) with videos related to

Pageof 25
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 21, 2004
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes miceHimani Bisht, Anjeanette Roberts, Leatrice Vogel, et al.
Journal of Virology|December 25, 2009
Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunityBaibaswata Nayak, Sachin Kumar, Joshua M DiNapoli, et al.
Vaccine|December 20, 2011
Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young childrenRuth A Karron, Bhagvanji Thumar, Elizabeth Schappell, et al.
Vaccine|June 21, 2005
Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxovirusesSheila M Nolan, Sonja R Surman, Emerito Amaro-Carambot, et al.
Vaccine|December 21, 2005
Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidatesEmmalene J Bartlett, Emerito Amaro-Carambot, Sonja R Surman, et al.
The Pediatric Infectious Disease Journal|August 11, 2011
The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young childrenRuth A Karron, Roberta Casey, Bhagvanji Thumar, et al.
Journal of Virology|July 31, 2015
Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV VaccineNatalie Mackow, Emérito Amaro-Carambot, Bo Liang, et al.
Plos Pathogens|December 29, 2021
Reversion mutations in phosphoprotein P of a codon-pair-deoptimized human respiratory syncytial virus confer increased transcription, immunogenicity, and genetic stability without loss of attenuationJessica W Chen, Lijuan Yang, Celia Santos, et al.
Science Translational Medicine|November 6, 2015
A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in childrenRuth A Karron, Cindy Luongo, Bhagvanji Thumar, et al.
Vaccine|August 4, 2009
Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidatesCindy Luongo, Lijuan Yang, Christine C Winter, et al.
Pageof 25

Showing results (121-130 of 247) with videos related to

Sort By:
Pageof 25
Proceedings of the National Academy of Sciences of the United States of America|April 21, 2004
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes miceHimani Bisht, Anjeanette Roberts, Leatrice Vogel, et al.
Journal of Virology|December 25, 2009
Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunityBaibaswata Nayak, Sachin Kumar, Joshua M DiNapoli, et al.
Vaccine|December 20, 2011
Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young childrenRuth A Karron, Bhagvanji Thumar, Elizabeth Schappell, et al.
Vaccine|June 21, 2005
Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxovirusesSheila M Nolan, Sonja R Surman, Emerito Amaro-Carambot, et al.
Vaccine|December 21, 2005
Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidatesEmmalene J Bartlett, Emerito Amaro-Carambot, Sonja R Surman, et al.
The Pediatric Infectious Disease Journal|August 11, 2011
The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young childrenRuth A Karron, Roberta Casey, Bhagvanji Thumar, et al.
Journal of Virology|July 31, 2015
Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV VaccineNatalie Mackow, Emérito Amaro-Carambot, Bo Liang, et al.
Plos Pathogens|December 29, 2021
Reversion mutations in phosphoprotein P of a codon-pair-deoptimized human respiratory syncytial virus confer increased transcription, immunogenicity, and genetic stability without loss of attenuationJessica W Chen, Lijuan Yang, Celia Santos, et al.
Science Translational Medicine|November 6, 2015
A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in childrenRuth A Karron, Cindy Luongo, Bhagvanji Thumar, et al.
Vaccine|August 4, 2009
Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidatesCindy Luongo, Lijuan Yang, Christine C Winter, et al.
Pageof 25